drugset / Trial / NCT02515838

Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

NCT02515838

Phase 2 Completed 147 enrolled Modus Therapeutics AB Ergomed GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects with Sickle-Cell Disease (SCD).

Timeline

Start
2015-07
Primary completion
2019-05
Completion
2019-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevuparin Other / unclassified 18 mg/kg Intravenous

Indications